Format

Send to

Choose Destination
Transplantation. 2007 Apr 27;83(8):1093-7.

Pitavastatin suppresses acute and chronic rejection in murine cardiac allografts.

Author information

1
Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan. jsuzuki.cvm@tmd.ac.jp

Abstract

INTRODUCTION:

HMG-CoA reductase inhibitors play several roles in the maintenance of organ transplants. We investigated the role of pitavastatin, a potent and newly developed HMG-CoA reductase inhibitor, in cardiac allograft rejection and mechanism of graft arterial disease (GAD) suppression.

METHODS:

Balb/c mice hearts were transplanted into C3H/He mice (a full allomismatch combination) to assess acute rejection or C57BL/6 hearts into B6.C-H2(<bm12>)KhEg (a class II mismatch combination) to examine the extent of GAD. Pitavastatin was administered orally to mice everyday (3 mg/kg/day). To assess the effect in acute rejection, mixed lymphocyte reaction was performed and cytokine mRNA expression was examined with ribonuclease protection assay.

RESULTS:

Pitavastatin significantly prolonged allograft survival. Lymphocyte proliferation was inhibited by pitavastatin, and RPA showed down-regulation of interleukin-6 in pitavastatin-treated cardiac allografts. Allografts in the pitavastatin-treated group after 8 weeks showed less GAD compared with the control group. In vitro, pitavastatin suppressed the smooth muscle cell proliferation in response to activated T cells and inhibited extracellular signal-regulated kinase 1/2 activation.

CONCLUSION:

Pitavastatin could be effective in the suppression of acute rejection and GAD development in cardiac transplantation.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center